February 10, 2016

Meet us at the Annual Biomarkers Congress 2016

This Biomarker Congress (February 25-26, Manchester, UK) creates the perfect forum to showcase Biogazelle’s RNA biomarker discovery platform. Our platform is designed to unlock the untapped potential of more than 80 000 candidate RNA biomarkers and to define robust biomarker signatures. This platform is driving our own RNA biomarker discovery programs and accelerates that of our customers and partners.

November 5, 2015

Exiqon’s antisense products are best in class in new comparative study

Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative study on technologies for functional knockdown.

The study was conducted by Biogazelle, a Belgium company focusing on nucleic acid-based drug technologies for RNA-targeting therapies in cancer. Within this in vitro study, Exiqon’s Antisense LNA™ GapmeR technology was shown to be superior to other technologies tested for knockdown capability of lncRNAs (long non-coding RNAs).

October 20, 2015

RXi Pharmaceuticals announces remarkable and positive results with its Novel Self-Delivering RNAi Platform: Potent Reduction of Long Non-coding RNAs Demonstrated in Collaboration with Biogazelle

MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced positive results from a collaboration with Biogazelle NV.  Biogazelle is a company with a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs (lncRNA). 

October 15, 2015

Biogazelle and Ionis Pharmaceuticals evaluate long non-coding RNAs to identify and validate novel targets for anti-cancer drugs

Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet clinical needs. As part of this collaboration, Isis will provide access to its proprietary antisense platform to Biogazelle for large-scale validation of therapeutic long non-coding RNA (lncRNA) targets from Biogazelle’s proprietary target identification pipeline.